Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: Prognostic significance of serum immunosuppressive acidic protein levels

Cancer Immunology, Immunotherapy

Volumn 52, Issue 9, 2003, Pages 555-560

  Ebina, Takusaburo ^a   Ogama, Naoko ^a   Shimanuki, Hiroko ^a   Kubota, Tomoka ^a   Isono, Noriko ^a  

^a MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

CD56+ cell; Immunocell therapy; Immunosuppressive acidic protein; Lung cancer; Quality of life

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; IMMUNOSUPPRESSIVE ACID PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOCELL THERAPY; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; KILLER CELL; LUNG CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NATURAL KILLER CELL; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD56; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, LYMPHOKINE-ACTIVATED; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; PILOT PROJECTS; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 0042355179     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0393-8     Document Type: Article

References (23)

1. Arora PK (1989) Neuromodulation of natural killer cell activity. In: Goetzl EJ, Spector NH (eds) Neuroimmune networks. Liss, New York, p 39
2. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305
3. Bauer S, Groh V, Wu J, Steinle, A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727
4. Blalock JE (1989) A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev 69:1
5. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1723
6. Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 236:799
7. Ebina T, Murata K, Tamura K (1994) Antitumor effect of intratumoral administration of biological response modifiers: induction of immunosuppressive acidic protein, a type of α1-acid glycoprotein, in mice. Jpn J Cancer Res 85:93
8. Ebina T, Fujimiya Y, Yamaguchi T, Ogama N, Sasaki H, Isono N, Suzuki Y, Katakura R, Tanaka K, Nagata K, Takano S, Uno K, Kishida T (1996) The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. Biotherapy 11:241
9. Ebina T, Ogama N, Shimanuki H, Kubota T, Isono N (2001) Effector mechanisms and clinical response of BAK (BRM-activated killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (neuro-immune-endocrine) cells. Microbiol Immunol 45:403
10. - γδ T cells from glioblastoma patients. Clin Cancer Res 3:633
11. Gamen S, Hanson DA, Kaspar A, Naval J, Krensky AM, Anel A (1998) Granulysin-induced apoptosis: I. involvement of at least two distinct pathways. J Immunol 161:1758
12. Gilman SC, Schwarz JM, Milner RJ, Bloom FE, Feldman JD (1982) Beta endorphin enhances lymphocyte proliferative responses. Proc Natl Acad Sci USA 79:4226
13. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N (2001) Targeting of tumor cells for human γδT cells by non-peptide antigens. J Immunol 167:5092
14. Kishi A, Takamori Y, Ogawa K, Takano S, Tomita S, Tanigawa M, Niman M, Kishida T, Fujita S (2001) Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer. Cancer Immunol Immunother 10:1
15. Lanier LL, Testi R, Bimdl J, Phillips JH (1989) Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 169:2233.
16. Lorish CD, Maisiak R (1986) The face scale: a brief, nonverbal method for assessing patient mood. Arth and Rheum 29:906
17. Rosenberg SA (1998) An immunotherapy of cancer using interleukin-2. Immunol Today 9:58
18. Sakamoto J, Koike A, Saji S, Teramura S, Ohashi Y, Nakazato H (1992) Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK. Surg Today 22:530
19. Sakamoto J, Teramukai S, Koike A, Saji S, Ohashi Y, Nakazato H (1996) Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma: findings from three independent clinical trials. Cancer 77:2206
20. Shavit Y, Terman GW, Martin FC, Lewis JW, Liebeskind J C, Gale RP (1985) Stress, opioid peptides, the immune system, and cancer. J Immunol 135:834
21. Tamura K, Shibata Y, Matsuda Y, Ishida N (1981) Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res. 41:3244
22. Thiery JP, Brackenbury R, Rutishausen U, Edelman GH (1977) Adhesion among neural cells of the chick embyo: II. purification and characterization of a cell adhesion molecule from neural retina. J Biol Chem 252:6841
23. Yabe N, Komiya K, Takezono T, Matsui H (1993) Lysozoyme as a regulator of interleukin-2-activated lymphocyte proliferation. In Vitro Cell Dev Biol 29:795